183 related articles for article (PubMed ID: 37498227)
1. Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report.
Zhang Y; Liu X; Liang H; Liu W; Wang H; Li T
J Int Med Res; 2023 Jul; 51(7):3000605231187942. PubMed ID: 37498227
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
3. Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
Li T; Hu W; Jin L; Yin X; Kang D; Piao L
Front Oncol; 2023; 13():1164368. PubMed ID: 37124509
[TBL] [Abstract][Full Text] [Related]
4. Esophageal Neuroendocrine Carcinoma With Pathological Complete Response After Neoadjuvant Chemotherapy Followed by Robot-assisted Surgery: A Case Report.
Hirano K; Hirohata R; Hamai Y; Yamaguchi S; Emi M; Yoshikawa T; Ohsawa M; Okada M
Anticancer Res; 2023 Jul; 43(7):3289-3293. PubMed ID: 37351985
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population-based study.
Chen C; Hu H; Zheng Z; Yang Y; Chen W; Qiao X; Li P; Zhang S
Cancer Med; 2022 Dec; 11(24):4935-4945. PubMed ID: 35596661
[TBL] [Abstract][Full Text] [Related]
7. Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
Zhou N; Chen Y; Huang Q; Jiang L; Liao H; Gou H; Lu Y; Che G; Zhang Y
Front Immunol; 2023; 14():1111325. PubMed ID: 36911701
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature.
Yin X; Li X; Li M; She Q; Liu Y; Chen X; Ma S; Ma Q; Huang Z; Xu L; Huang X; Zhan Z; Che X
Front Med (Lausanne); 2022; 9():891958. PubMed ID: 35685408
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report.
Peng S; Huang H; Zhu X; Chen J; Ding X; Wang F; Chen L; Lu Z
Exp Ther Med; 2024 May; 27(5):178. PubMed ID: 38515651
[TBL] [Abstract][Full Text] [Related]
10. A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy.
Cai R; Liu Y; Sha H; Yu J; Fang Y; Zhou G; Shen B
Heliyon; 2023 Nov; 9(11):e21902. PubMed ID: 38027958
[TBL] [Abstract][Full Text] [Related]
11. Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma.
Zhang D; Liang J; Lv Y; Huang X; Guo W
Medicine (Baltimore); 2022 Dec; 101(52):e32459. PubMed ID: 36596035
[TBL] [Abstract][Full Text] [Related]
12. Nationwide survey of neuroendocrine carcinoma of the esophagus: a multicenter study conducted among institutions accredited by the Japan Esophageal Society.
Sohda M; Kuwano H; Saeki H; Miyazaki T; Sakai M; Kakeji Y; Toh Y; Doki Y; Matsubara H
J Gastroenterol; 2021 Apr; 56(4):350-359. PubMed ID: 33582864
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features, treatment modalities, and prognosis of esophageal neuroendocrine carcinoma: A single-center retrospective study.
Zhang Y; Liao JT; Lin Y; Liu C; Wu ZH; Yu B; Sun S; Yu H; Hui XH; Wu XH; Zhao XM; Wang HJ; Zheng Q; Li Y; Hu ZH; Wang JL
J Dig Dis; 2023; 24(8-9):472-479. PubMed ID: 37596865
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
15. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.
Liu L; Zhang X; Zhou L; Yang T; Qiao Y; Jiang X
Medicine (Baltimore); 2021 Sep; 100(35):e27138. PubMed ID: 34477165
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Yang X; Xiang M; Geng L; Wen Y; Du X
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
[TBL] [Abstract][Full Text] [Related]
18. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
19. [Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer].
Lu S; Yu XM; Hu YP; Ma ZY; Li XY; Li WD; Liu YP; Wang D; Wang XW; Wang ZH; Wu JX; Zhong DS; Li GF; He WY; Bao YY; Yuan Y; Fan JH
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):358-367. PubMed ID: 37078218
[No Abstract] [Full Text] [Related]
20. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
